Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring AIDS-Related Opportunistic Infections, Zidovudine, HIV Protease Inhibitors, CD4 Lymphocyte Count, Lamivudine, Pneumonia, Nelfinavir, Reverse Transcriptase Inhibitors, Antiretroviral Therapy, Highly Active, Efavirenz, Intensive Care Units, Sepsis
Eligibility Criteria
Inclusion Criteria HIV-1 infection CD4 cell count less than 350 cells/mm3 within 120 hours prior to study entry Admission to an ICA (or to any part of the hospital with an arterial blood gas PaO2/FiO2 ratio of < 200 or SAPS I score > 13) within 120 hours prior to study entry Admitted to the hospital for sepsis, pneumonia, or other AIDS-defining disease Acceptable methods of contraception Exclusion Criteria Known resistance or intolerance to antiretroviral drugs that precludes use of an effective HAART regimen of FDA approved drugs, excluding abacavir or full-dose ritonavir More than 7 days of HAART (a regimen of at least 3 drugs that includes a protease inhibitor, a nonnucleoside reverse transcriptase inhibitor, or three nucleoside analogues) within 4 weeks prior to study entry Investigational drug within 14 days prior to study entry Pregnant or breast-feeding Allergy or sensitivity to any of the study drugs that cannot be substituted with another drug CNS mass lesion or bacterial meningitis Certain medications Uncertain availability for 6 month course of study Require regular stomach suctioning
Sites / Locations
- Univ of Southern California
- Univ of California, San Diego
- Univ of California San Francisco
- Univ of Miami School of Medicine
- Johns Hopkins Hosp
- Washington Univ School of Medicine
- Beth Israel Med Ctr
- Duke Univ Med Ctr
- Univ of Washington